Abstract
Background: Aromatase inhibitor–induced arthralgia is common in patients with early-stage breast cancer who are on aromatase inhibitors, potentially compromising adherence and outcomes. We developed and validated prediction models for short-term and longer-term aromatase inhibitor–induced arthralgia. Methods: Postmenopausal patients with stage I to III breast cancer on adjuvant aromatase inhibitors in the Chronic Toxicities Related to Treatment in Patients With Localized Cancer (CANTO; NCT01993498) trial were included. The primary outcome was aromatase inhibitor–induced arthralgia (any-grade articular or muscular pain; Common Terminology Criteria for Adverse Events, version 4.0) at year 1 and year 4 cohort visits. Baseline clinical, behavioral, treatment-related, and patient-reported (European Organisation for Research and Treatment of Cancer Quality of Life Group Core Questionnaire, Hospital Anxiety and Depression Scale) variables were modeled using multivariable logistic regression and bootstrapping in development and temporal validation cohorts. Baseline inflammatory markers were examined in a subcohort. Results: The year 1 and year 4 development cohorts included 3065 and 2390 patients (mean [SD] age = 64.0 [7.2] years and 63.7 [6.9] years), respectively. Aromatase inhibitor–induced arthralgia occurred in 61.3% of year 1 patients and 66.1% of year 4 patients. Validation cohorts included 1313 year 1 patients and 1009 year 4 patients with similar characteristics. Across models, higher body mass index, greater baseline fatigue, prior articular or muscular disease, chemotherapy exposure, and preexisting pain were associated with subsequent aromatase inhibitor–induced arthralgia; anastrozole use was associated with aromatase inhibitor–induced arthralgia at year 4. The area under the curve was 0.62 to 0.65 in development cohorts and 0.61 to 0.67 in validation cohorts. In the biomarker subcohort (n = 637), higher baseline interleukin 8 level was associated with lower odds of year 1 aromatase inhibitor–induced arthralgia (odds ratio = 0.74, 95% CI = 0.56 to 0.98). Conclusions: Using baseline clinical and patient-reported data, we generated models to identify patients at increased risk of early and persistent aromatase inhibitor–induced arthralgia. Although model performance was modest, risk stratification could help trigger stepped-care pathways to optimize aromatase inhibitor adherence and outcomes. Interleukin 8 association requires independent replication. Trial Registration: ClinicalTrials.gov identifier NCT01993498.
Funding Information
  • Fondation French National Research Agency
  • American Society of Clinical Oncology (ASCO) Foundation
  • Career Pathway Grant in Symptom Management from Conquer Cancer
  • American Society of Clinical Oncology
  • Rising Tide Foundation for Clinical Cancer Research
  • Foundation ARC (ARCPGA20220100044014882)
  • Agence Nationale de la Recherche (ANR-10-COHO-0004)

This publication has 64 references indexed in Scilit: